BSX
Boston Scientific Corp
NYSE: BSX · HEALTHCARE · MEDICAL DEVICES
$46.91
-0.55% today
Updated 2026-06-12
Market cap
$70.87B
P/E ratio
19.95
P/S ratio
3.44x
EPS (TTM)
$2.39
Dividend yield
—
52W range
$47 – $110
Volume
20.4M
WallStSmart proprietary scores
76
out of 100
Grade: B+
Buy
Investment rating
8.0
Growth
A6.3
Quality
B7.0
Profitability
B+5.3
Valuation
C+5/9
Piotroski F-Score
Moderate
—
Altman Z-Score
—
—
Industry rank
—
View all highly rated stocks (75+) →202 stocks currently score above 75
Price targets
Analyst target
$104.48
+122.72%
12-Month target
$58.31
+24.30%
Intrinsic (DCF)
$37.35
Margin of safety
-29.38%
7 Strong Buy20 Buy4 Hold0 Sell0 Strong Sell
Price chart
Stock snapshot
Strengths
+ Free cash flow $171.00M — positive
+ Revenue growth 11.60% QoQ
+ Debt/equity 0.43x — low leverage
Risks
- 29.38% above intrinsic value
Key financials
Revenue Net Income Free Cash Flow
| Metric | 2022 | 2023 | 2024 | 2025 | TTM | 2026 (E) |
|---|---|---|---|---|---|---|
| Revenue | $12.68B | $14.24B | $16.75B | $20.07B | $20.61B | $22.5B |
| Net income | $698.00M | $1.59B | $1.85B | $2.89B | $1.34B | — |
| EPS | — | — | — | — | $2.39 | $3.50 |
| Free cash flow | $914.00M | $1.70B | $2.65B | $3.66B | $171.00M | — |
| Profit margin | 5.50% | 11.19% | 11.07% | 14.38% | 17.30% | — |
Recent insider activity
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| 2026-05-28 | MAHONEY, MICHAEL F | Sale | 386,755 | — |
| 2026-05-20 | PEGUS, CHERYL | Buy | 1,770 | $56.49 |
| 2026-05-20 | LUDWIG, EDWARD J | Buy | 3,580 | $56.68 |
Peer comparison
Smart narrative
Boston Scientific Corp trades at $46.91. representing a P/E of 19.95x trailing earnings. Our Smart Value Score of 76/100 indicates the stock is good. The company scores 5/9 on the Piotroski F-Score. TTM revenue stands at $20.61B. with profit margins at 17.30%. Our DCF model estimates intrinsic value at $37.35.
Frequently asked questions
What is Boston Scientific Corp's stock price?
Boston Scientific Corp (BSX) trades at $46.91, on a P/E of 20.0x and a P/S of 3.4x. Those multiples show what the market is paying for each dollar of earnings and sales, which is the real starting point for judging whether the price is reasonable.
Is Boston Scientific Corp overvalued?
Boston Scientific Corp carries a Smart Value Score of 76/100 (Grade B+), which we rate Buy. That score blends growth, quality, and valuation into one read. On valuation specifically, our conservative DCF puts intrinsic value at $37.35 against the $46.91 price, so on cash flow terms the market is paying a premium for Boston Scientific Corp's growth. The Buy rating reflects that growth and quality, while the DCF flags that the price already assumes a lot.
What is the price target of Boston Scientific Corp (BSX)?
The 12-month analyst consensus target is $104.48, about 122.7% above the current $46.91. A consensus target is the average of Wall Street's 12-month forecasts, so it works as a sentiment gauge rather than a guarantee, and it resets with every earnings cycle.
What is the future stock price of BSX by 2030?
Our research-backed model puts the 2030 base case at $263.84, built from revenue projections, a growth-adjusted P/S multiple, net debt, and share dilution. It is a scenario rather than a prediction, and the bull and bear cases around it matter more than the single number when you are sizing a position.
What is the intrinsic value of Boston Scientific Corp (BSX)?
Our DCF model estimates intrinsic value at $37.35, a -29.4% margin of safety versus today's $46.91. Intrinsic value is what the projected cash flows are worth today. A negative reading means the price is running ahead of that conservative estimate, leaving little downside cushion if growth slows.
What is Boston Scientific Corp's revenue?
Boston Scientific Corp's trailing twelve-month revenue is $20.61B, and our model projects it reaching about $32.25B by 2030. Revenue scale anchors the valuation multiples and shows whether growth is reaching the top line, so it is best read alongside margin and growth trends to see if that revenue is getting more profitable over time.
Company info
SectorHEALTHCARE
IndustryMEDICAL DEVICES
CountryUSA
ExchangeNYSE
CurrencyUSD
Quick metrics
P/S ratio3.44x
ROE13.74%
Beta0.62
50D MA$59.22
200D MA$84.67
Shares out1.49B
Float1.48B
Short ratio—
Avg volume20.4M
Performance
1 week+0.00%
1 month-7.84%
3 months-29.77%
YTD-49.08%
1 year—
3 years—
5 years—